BenevolentAI says second target identified by AstraZeneca collaboration
BenevolentAI (OTC:BAIVF) said that AstraZeneca PLC (LSE:AZN) has identified a target for systemic lupus erythematosus (SLE) using the formers artificial...…
60,750€
0,41%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
Update on Imfinzi ADJUVANT BR.31 trial
25 June 2024
Update on ADJUVANT BR.31 Phase III trial
of Imfinzi in non-small cell lung cancer
High-level results from the ADJUVANT BR.31 Phase III trial, sponsored by…
Imfinzi improved EFS and OS in bladder cancer
25 June 2024
Imfinzi demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA…
Barclays belässt Roche auf Equal Weight - Ziel 230 Franken
LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat Roche nach Gesprächen mit einer einflussreichen Person aus einem der größten…
Barclays belässt Novartis auf Underweight - Ziel 85 Franken
LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat Novartis nach Gesprächen mit einer einflussreichen Person aus einem der größten…
Barclays belässt Astrazeneca auf Overweight - Ziel 13500 Pence
LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat Astrazeneca nach Gesprächen mit einer einflussreichen Person aus einem der größten…
Global Genome Editing Market Size To Worth USD 34.75 Billion By 2033 | CAGR Of 16.19%
The Global Genome Editing Market Size was Valued at USD 7.75 Billion in 2023 and the Worldwide Genome Editing Market…
Pharma Stock Roundup: FDA Nod to MRKs New Jab & Expanded Use of ABBV & AZN Drugs
FDA approves Mercks (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVies (ABBV) Skyrizi and AstraZenecas (AZN)…
Global Anal Fissure Treatment Market Size To Exceed USD 1986.1 Million By 2033 | CAGR Of 5.51%
The Global Anal Fissure Treatment Market Size was Valued at USD 1161.3 Million in 2023 and the Worldwide Anal Fissure…
Trading in Trill Impact’s portfolio company Cinclus Pharma commences on Nasdaq Stockholm
The Swedish biopharmaceutical company has successfully raised capital for Phase 3 clinical development
Cinclus Pharma Holding AB (publ) (“Cinclus Pharma”) is…